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Abstract
Background: The development of polymerase chain reaction (PCR)-based methods for the detection of known
mutations has facilitated detecting specific red blood cell (RBC) enzyme deficiencies. We carried out a study on
glucose-6-phosphate dehydrogenase (G6PD) deficient subjects in Jeddah to evaluate the molecular characteristics
of this enzyme deficiency and the frequency of nucleotide1311 and IVS-XI-93 polymorphisms in the glucose-6-
phosphate dehydrogenase gene.
Results: A total of 1584 unrelated Saudis (984 neonates and 600 adults) were screened for glucose-6-phosphate
dehydrogenase deficiency. The prevalence of glucose-6-phosphate dehydrogenase deficiency was 6.9% (n = 110).
G6PD Mediterranean mutation was observed in 98 (89.1%) cases, G6PD Aures in 11 (10.0%) cases, and G6PD
Chatham in 1 (0.9%) case. None of the samples showed G6PD A‾ mutation. Samples from 29 deficient subjects
(25 males and 4 females) were examined for polymorphism. The association of two polymorphisms of exon/intron
11 (c.1311T/IVS-XI-93C) was observed in 14 (42.4%) of 33 chromosomes studied. This association was found in 9
(31.0%) carriers of G6PD Mediterranean and in 4 (13.8%) carriers of G6PD Aures.
Conclusions: The majority of mutations were G6PD Mediterranean, followed by G6PD Aures and < 1% G6PD
Chatham. We conclude that 1311T is a frequent polymorphism in subjects with G6PD Mediterranean and Aures
variants in Jeddah.
Background
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is
one of the most common enzymopathies, accounting for
over 400 million cases worldwide [1-3]. Most cases of
glucose-6-phosphate dehydrogenase deficiency occur in
males [4]. Affected individuals are usually asymptomatic,
and go through life without being aware of their defi-
ciency. They are, however, at risk of having acute hemoly-
tic crises in response to infection, eating fava beans, and to
drugs having a high oxidation potential [5].
Based on biochemical properties, ethnic origin, and
clinical presentation, more than 400 variants of glucose-
6-phosphate dehydrogenase have been distinguished in
the past. Characterization at the DNA level reduced this
number to about 182; these are distributed among 4
classes based on activity and clinical manifestation [6]. In
the Kingdom of Saudi Arabia, studies have described the
prevalence of glucose-6-phosphate dehydrogenase defi-
ciency and associated enzyme variants, with G6PD Medi-
terranean found to be the most common [7-10]. In the
current study, 110 cases of glucose-6-phosphate dehydro-
genase deficiency were studied at the molecular level to
evaluate the molecular heterogeneity of this deficiency
and the frequency of the silent C/T polymorphism at nt
1311 in glucose-6-phosphate dehydrogenase deficient
subjects in the Jeddah area.
Methods
Unrelated Saudi adults and neonates were screened for
glucose-6-phosphate dehydrogenase deficiency. For
adults, blood samples were collected from the general
population; this included blood donors, university stu-
dents, and health-care workers. All neonates delivered
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versity Hospital and King Fahd Armed Force Hospital in
Jeddah were also screened for glucose-6-phosphate dehy-
drogenase deficiency. Consent was obtained from the
participants or their parents prior to conducting the
research. The study was approved by the Biomedical
Ethical Research Committee of the Faculty of Medicine
of King Abdulaziz University (Reference No. 530-11)
Red blood cell glucose-6-phosphate dehydrogenase
activity was measured with quantitative kits that use
Sigma glucose-6-phosphate dehydrogenase H control
(Sigma Medical, USA). The kits use the chemical reaction
described by Beutler [11], with NADPH production mea-
sured at 340 nm in kinetic mode (change in optical den-
sity per minute). Values < 4.6 U/g Hb were considered
deficient [11,12].
Genomic DNA was extracted from peripheral blood leu-
kocytes of the deficient subjects by standard methods
(proteinase K digestion, phenol/isoamyl alcohol/chloro-
form extraction and ethanol precipitation) [11,13].
The most frequent glucose-6-phosphate dehydrogenase
variants were determined by restriction fragment length
polymorphism (RFLP). The G6PD Aures mutation is
located in exon 3 (c.143T > C, p.Ile48Thr), G6PD A‾
mutations are located in exon 4 (c.202 G > A, p.Val68 >
Met) and exon 5 (c.376A > G, p.Asn126Asp), and G6PD
Mediterranean is in exon 6 (c.563C > T, p.Ser188Phe).
Therefore, these DNA fragments were amplified using pri-
mers as listed in Table 1. For the reactions, 500 ng DNA
were amplified on a GeneAmp
® PCR System 2700 thermal
cycler (Applied BioSystems, Foster City, CA, USA) with
1.25 U AmpliTaq
® DNA Polymerase (Roche, New Jersey,
NJ, USA) and 10 pmol of each primer, 0.2 mM of each
dNTP, and1.5 mM MgCl2. The final buffer comprised
16.6 mM (NH4)2SO4,6 7m MT r i s - C l ,p H8 . 8 ,1 . 5m M
MgCl2,6 7m MN a 2EDTA, pH 8.0, 70 μg BSA, and 10 mM
b-mercaptoethanol. An initial denaturation step at 94°C
for 5 minutes was followed by 35 cycles of denaturation at
94°C for 10 seconds, annealing at 61°C for 30 seconds, and
extension at 72°C for 30 seconds. A final extension at 72°C
for 7 minutes completed the cycling reaction. For RFLP
studies, 18 μl of each PCR product was restricted accord-
ing to the manufacturer’s recommendation with 20 IU of
each corresponding enzyme. Exon 3 was cleaved with
BglII, exon 4 with NlaIII, exon 5 with FokI, and exon
6 with MboII. Ten microliters of the digestion products
were size fractionated by electrophoresis through polya-
crylamide gels (6%), stained with ethidium bromide
(0.25 μg/ml), and analyzed by UV transillumination.
For molecular characterization of the remaining glu-
cose-6-phosphate dehydrogenase deficient subjects and
also for evaluating the frequency of nucleotide 1311C >
T polymorphism, the glucose-6-phosphate dehydrogen-
ase gene was entirely sequenced. Samples from glucose-
6-phosphate dehydrogenase deficient patients were sent
to the Department of Biochemistry and Genetics, Henri
Mondor University Hospital, Creteil, France for gene
sequencing. Different DNA fragments were amplified
using primers as listed in Table 1. The amplification reac-
tion was performed using 10% (v/v) dimethylsulphoxide
(DMSO) with 35 cycles of 1 minute denaturation at 94°C,
1 minute annealing at 56°C, and 1 minute extension at
72°C, followed by a final extension of 7 minute at 72°C.
Nucleotide sequencing of the PCR products was per-
formed with the forward and reverse primers using the
BigDye
® Terminator v3.1 Sequencing Kit (Applied Bio-
Systems) and analyzed on an automated sequencer (ABI
PRISM
® 3100 Genetic Analyzer; Applied BioSystems)
[3,14,15].
Results
A total of 1584 Saudis (984 neonates and 600 adults) were
screened for glucose-6-phosphate dehydrogenase defi-
ciency. One hundred and ten subjects (6.9%), including
Table 1 Primers used for identification of glucose-6-phosphate dehydrogenase defects
a
Analysis Analyzed Region Forward 5’®3’ Reverse 5’®3’
RFLP Analysis (Tm = 61°C) Exon 3 GTGGAGGATGATGTATGTAGGT AGGGCAGGGCACAGCTGTAA
Exon 4 TACAGTCGTGCCCTGCCCT CCGAAGCTGGCCATGCTGG
Exon 5 CTGTGTGTGTGTCTGTCTGTC GGAGGGCAACGGCAAGCCTT
Exon 6 GCAGCTGTGATCCTCACTCC GCAAGGTGGAGGAACTGACC
Gene sequencing (Tm = 56°C) Exons
1, 2
AAGCTCGGTAATGATAAGCACGC TGGAGCAGGCACTTCCTGG
Exons
3, 4, 5
GTGGAGGATGATGTATGTAGGT GGAGGGCAACGGCAAGCCTT
Exons
6, 7, 8
AGAGGGTCATCTGGGAACACAA CCTGGGACATGACAACTTGGG
Exons
9, 10, 11, 12, 13
TCTGTGGCCACAGTCATCCC CGCCCTCCTCCTTCCTTCTG
Abbreviations: A, alanine; C, cysteine; G, glycine; RFLP, restriction fragment length polymorphism; Tm, Anealing temperature; T, threonine
aAdapted from Moradkhani et al.[14]
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(58 males and 10 females) were deficient. G6PD Mediter-
ranean mutation was observed in 98 (89.1%) cases, G6PD
Aures in 11 (10.0%) cases, and G6PD Chatham in 1 (0.9%)
case. None of the samples showed G6PD A‾ mutation
(Table 2). Samples from 29 deficient subjects (25 males
and 4 females) were examined for polymorphism. The
nucleotide 1311T (p.Tyr437Tyr) polymorphism was
observed in 14 (42.4%) of 33 chromosomes studied (25
males and 4 females), and it was associated with G6PD
Mediterranean (n = 9; 31.0%) and G6PD Aures (n = 4;
13.8%) (Table 2).
Discussion
The availability of molecular studies by PCR and glucose-
6-phosphate dehydrogenase gene sequencing allows accu-
rate diagnosis and characterization of glucose-6-phosphate
dehydrogenase deficiency. In this study, we characterized
the molecular defects of the glucose-6-phosphate dehydro-
genase gene in deficient patients living in Jeddah. We
identified 3 variants; G6PD Mediterranean, G6PD Aures
and G6PD Chatham (Table 2).
Most of the patients (89.1%) in this study had the G6PD
Mediterranean mutation. Similarly, other authors found a
high prevalence of G6PD Mediterranean among glucose-
6-phosphate dehydrogenase deficient Saudis in a study
conducted in Jeddah [8,9]. These studies, however,
reported a lower frequency compared with our study;
51.1% and 38.1%, respectively. In one report evaluating the
frequency of glucose-6-phosphate dehydrogenase muta-
tion in 47 patients in Jeddah, 96% of the patients showed
C > T substitution at codon 188 of the glucose-6-phos-
phate dehydrogenase gene, characteristic of the Mediterra-
nean type [8]. Another study from the Al-Hassa and Al-
Qatif areas of Saudi Arabia’s Eastern Province also showed
G6PD Mediterranean as the most frequent variant, with a
prevalence of 45.9% and 36.5% for these 2 areas [10].
Studies conducted in several other areas of the Persian
Gulf region have also reported a high prevalence of the
Mediterranean variant; 55.5%i nt h eA l - A i nD i s t r i c to f
United Arab Emirates [16], 72.9% in Kuwait [17], 65.2% in
Oman [18], and 72.8% in Zanjan Province in Iran [19].
G6PD Aures was first described in Saudi Arabia by
Niazi et al. [20] in 1996. In the current study we identi-
fied G6PD Aures in 10% of the cases (Table 2). Similar
results were reported from Taif, in the Makkah province
of Saudi Arabia, with 12.3% of 49 deficient Saudis hav-
ing G6PD Aures [7]. The prevalence was slightly higher
in the United Arab Emirates (16.6%) [10] and much
lower in Kuwait (1.4%) [17].
The G6PD A
¯ variant was absent in our sample. Warsy
and El-Hazmi [21] identified the G6PD A
¯ in a study con-
ducted in several provinces in Saudi Arabia. The central
province had the lowest frequency (0.0325 in males and
0.0242 in females for A
+, 0.0074 in males and 0.0009 in
females for A
¯). This report primed us to authenticate the
data by sequencing all the samples. However a larger
sample size is needed for the verification of absence of
G6PD A
¯ mutation.
The low prevalence (0.9%) of G6PD Chatham mutation
in this study was less than that reported in another study
[7] from Taif, where the authors found a prevalence of
4.1%. The lower prevalence observed in our study could
b ed u et ot h ef a c tt h a tw eh a dal a r g e rs a m p l es i z e( 1 1 0 )
compared with 49 in their study.
In this study, the association of two polymorphisms, a
s i l e n tC / Ta tn t1 3 1 1( p . T y r 4 3 7 T y r )a n dT / Ca tn tI V S -
XI-93, was studied by direct sequencing of exon and
intron 11 of the glucose-6-phosphate dehydrogenase gene.
The c.1311T/IVS-XI-93C polymorphism was identified in
42.2% of 33 chromosomes studied. This result is compar-
able to that obtained from studies conducted in Bahraini
and Pakistani populations [22]. On the other hand, Kurdi-
Haidar et al. [23] reported the frequency of the c.1311T/
IVS-XI-93C polymorphism in only 14% of the subjects in a
study conducted in Saudi Arabia. This can be explained by
the low number of X chromosomes studied by the
authors. The 1311T polymorphism is frequently observed
Table 2 Summary of mutations detected in 110 deficient Saudi patients in Jeddah and the frequency of 1311T and
IVS-XI-93C polymorphisms
G6PD Variants Mutation Amplified Exon/Intron Number of Patients and
Percentage [n (%)]
Mediterranean c.563 C > T 6 98 (89.1%)
Aures c.143 T > C 3 11 (10.0%)
G6PD A
¯ c.202 G > A 4 0 (0%)
c.376 A > G 5 0 (0%)
Chatham c.1003 G > A 9 1 (0.9%)
Polymorphism
(33 chromosomes of 25 males and 4 females)
c. 1311T 11 14 (42.4%)
IVS-XI-93C Intron 11 21 (63.6)
1311T/IVS-XI-93C Exon/intron 11 14 (42.4%)
Abbreviations: A, alanine; C, cysteine; G, glycine; G6PD, glucose-6-phosphate dehydrogenase; T, threonine
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is less frequent in American and non Mediterranean
European countries [22,24].
The presence of the dual mutation (c.1311T/IVS-XI-
93C) has been proposed to be linked to glucose-6-phos-
phate dehydrogenase deficiency. This association was
frequently observed with G6PD Mediterranean and
G6PD Aures [25,26].
Conclusions
Molecular analysis of glucose-6-phosphate dehydrogen-
ase deficiency in this study conducted in Jeddah revealed
a higher prevalence of G6PD Mediterranean (89.1%) and
Aures (10.0%) compared with other studies from Saudi
Arabia. The absence of the African variant suggests
further studies with a larger sample size are warranted.
The nucleotide 1311T is a frequent polymorphism
observed in Saudi Arabia.
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